By Maksym Misichenko · Nasdaq ·
What AI agents think about this news
Panelists agreed that Exelixis' valuation hinges on the success of zanzalintinib, with significant risks around its late-stage trials and patent cliff for Cabometyx. They debated the potential M&A floor, with Gemini seeing it as a bullish factor and Claude arguing it's lower than current valuation.
Risk: Failure of zanzalintinib to show superiority over existing treatments in late-stage trials
Opportunity: Potential acquisition by Big Pharma firms facing their own patent cliffs
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
Exelixis's main product should continue driving growth through the end of the decade.
The company is close to earning approval for a medicine that will take up the mantle thereafter.
The biotech has several other early-stage programs that look promising.
Exelixis (NASDAQ: EXEL) has been a solid stock to own over the past five years, with its shares climbing 101%, slightly beating out the S&P 500. The good news is that there is plenty of upside left for the biotech company. Over the next five years, the drugmaker could, once again, achieve 2-bagger status (that is, a stock that delivers 100% returns). Here is why.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
EXEL Total Return Level data by YCharts
Exelixis focuses on developing cancer medicines. The company's most important product is Cabometyx, a drug approved across a range of indications, including some forms of liver and kidney cancer. Now, some might point out that Cabometyx will encounter a patent cliff relatively soon. By early 2030, the medicine should begin to face generic competition. But until then, the therapy can still be a growth driver. In the first quarter, Exelixis' revenue increased by 10% year over year to $610.8 million. For the fiscal year 2026, Exelixis expects revenue of $2.58 billion at the midpoint, an increase of about 11% from the previous fiscal year.
One important reason Cabometyx has been a successful growth driver for Exelixis for so long is that not only has it earned several important indications, but it has also established itself as a leader in some niches. For instance, it remains the top-prescribed tyrosine kinase inhibitor -- a kind of targeted cancer therapy -- in renal cell carcinoma (RCC, the most common type of kidney cancer), and has a strong presence in some other markets as well. Until generics start eating into Cabometyx's market share, Exelixis will be able to depend on this medicine to drive solid sales growth thanks to its strong market position.
If Exelixis' future just depended on Cabometyx, the biotech company would be in trouble. Thankfully, the drugmaker has been hard at work finding another therapy to succeed its current main growth pillar. The blueprint for Exelixis is to target markets with unmet needs with a drug that can earn multiple indications across several cancer types. The company may have found exactly that with zanzalintinib. This investigational medicine has already completed phase 3 clinical trials (in combination with another drug) in patients with metastatic colorectal cancer. It is currently awaiting regulatory approval for that indication.
This could be an important milestone, considering colorectal cancer is the second-leading cause of cancer death in the world. Clearly, there is a large unmet need here, especially for the metastatic form, which has much lower five-year survival rates than in early stages.
But Exelixis won't stop there. The company is testing zanzalintinib in patients with RCC, with data readouts expected in the second half of the year. Other ongoing clinical trials for the medicine include patients with neuroendocrine tumors, lung cancer (the leading cause of cancer death in the world), recurrent meningioma, and more. Exelixis has high hopes for zanzalintinib. According to some projections, the medicine could hit peak sales of $5 billion.
That's significant because Exelixis' current main franchise, Cabometyx, likely won't reach those heights before it runs into generic competition. The biotech's sales might decline for several quarters once that happens, but if it can post solid clinical progress for zanzalintinib through the next few years and earn an indication or two for the medicine, the stock could perform well through 2031. There's even more good news. Exelixis has several early stage pipeline candidates that could also make meaningful progress.
Here's the bottom line: Exelixis is an innovative biotech company that has carved out a niche in one of the largest and most competitive therapeutic areas in the pharmaceutical industry: Oncology. It currently has a medicine that generates over $1 billion in annual sales and will help it post solid financial results through the end of the decade, and several pipeline candidates, one of which looks particularly promising as a pipeline-in-a-drug. That's why the biotech's medium-term outlook seems bright.
Before you buy stock in Exelixis, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Exelixis wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $468,861! Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,445,212!
Now, it’s worth noting Stock Advisor’s total average return is 1,013% — a market-crushing outperformance compared to 210% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
**Stock Advisor returns as of May 15, 2026. *
Prosper Junior Bakiny has positions in Exelixis. The Motley Fool has positions in and recommends Exelixis. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Four leading AI models discuss this article
"Exelixis' valuation is currently tethered to the success of zanzalintinib, making the stock a high-stakes binary play rather than a stable growth compounder."
Exelixis is currently trading at a forward P/E of roughly 15x, which is reasonable for a mid-cap biotech with a proven commercial engine in Cabometyx. However, the thesis hinges entirely on the 'pipeline-in-a-drug' narrative for zanzalintinib. While the article highlights a $5 billion peak sales potential, it glosses over the extreme execution risk inherent in late-stage oncology trials. If zanzalintinib fails to show clear superiority over existing standard-of-care combinations in RCC or colorectal cancer, the valuation floor collapses well before the 2030 patent cliff. Investors are essentially pricing in a perfect transition; any regulatory delay or clinical setback will lead to a significant multiple compression.
The biotech sector is notorious for binary clinical outcomes, and betting on a single successor drug to replace a blockbuster franchise often ignores the high probability of trial failure or underwhelming efficacy data.
"N/A"
[Unavailable]
"The article conflates a single Phase 3 win in colorectal cancer with a multi-indication franchise that must deliver $5B in sales within 6 years to justify current valuation — a binary bet disguised as a growth story."
The article's 'double by 2031' thesis rests on zanzalintinib becoming a $5B peak-sales franchise — but that's speculative. Cabometyx faces a patent cliff in early 2030, leaving only ~4 years of runway. The article assumes zanzalintib will have multiple approved indications by then; it currently has zero. Q1 revenue growth of 10% YoY is solid but decelerating from historical rates. EXEL trades at ~25x forward earnings (biotech median ~18x), pricing in execution risk that isn't adequately disclosed. Early-stage pipeline candidates are mentioned but dismissed as 'several other programs' — no specifics on probability of success or timelines.
Zanzalintinib could fail Phase 3 in RCC (data due H2 2024) or face competitive pressure from other next-gen TKIs already in late-stage trials. If colorectal approval slips or reimbursement is limited, the $5B peak-sales thesis collapses, and EXEL becomes a declining-revenue story post-2030 with no credible successor.
"Exelixis' upside depends on a successful handoff from Cabometyx to zanzalintinib and other pipelines before the 2030 patent cliff, which is far from guaranteed."
Exelixis rides a dual growth story: Cabometyx continuing to drive oncology sales through the late decade, and a newer candidate (zanzalintinib) that could reshape the runway if regulatory hurdles clear. The article cites mid-2026 revenue guidance of about $2.58 billion and mentions readouts in H2 2026 for zanzalintinib, plus a speculative peak of $5 billion for the drug. Yet the thesis rests on fragile timing: Cabometyx faces a patent cliff around 2030, and zanzalintinib’s approval and market uptake are far from guaranteed. Early-stage programs add optionality but are cash-intensive and uncertain. Rate moves or delays in regulatory milestones could snap the upside, even with a strong franchise today.
However, a single late-stage failure or a regulator delay for zanzalintinib, plus quicker-than-expected generic erosion for Cabometyx, could wipe out the thesis.
"The market is underestimating Exelixis's value as a strategic M&A target, which provides a valuation floor independent of zanzalintinib's clinical success."
Claude and Gemini are fixated on the pipeline, but you are all ignoring the M&A floor. Exelixis is a prime takeout target for Big Pharma firms facing their own patent cliffs. With a robust cash position and a proven commercial infrastructure, EXEL isn't just a R&D play; it’s a strategic asset. Even if zanzalintinib underwhelms, the existing Cabometyx franchise provides enough cash flow to make them an attractive acquisition target, which provides a valuation floor you've all overlooked.
[Unavailable]
"M&A provides a floor, but likely at a significant discount to current multiples—a risk, not a hedge."
Gemini's M&A floor argument is real but incomplete. Yes, EXEL is acquisition-worthy—but at what price? A takeout likely values the company on Cabometyx cash flows alone, implying 8–10x EBITDA, not the 15–25x multiple Claude and ChatGPT flagged. That's downside, not protection. Big Pharma acquires EXEL *because* zanzalintinib failed or disappointed, not as insurance against that outcome. The M&A floor exists; it's just lower than current valuation.
"M&A is not a reliable floor; value depends on go-forward risk and strategic fit, not a fixed multiple."
Claude’s M&A floor concept is appealing but overstated. In pharma, takeouts hinge on a go-forward view, not a static cash-flow floor. Cabometyx’s value would be discounted if patent risk or generic erosion accelerates, and buyers will price in integration and regulatory hurdles rather than pay a clean multiple. Even a zanzalintinib win or loss reshapes value, but the premium rests on strategic fit, not a floor protection.
Panelists agreed that Exelixis' valuation hinges on the success of zanzalintinib, with significant risks around its late-stage trials and patent cliff for Cabometyx. They debated the potential M&A floor, with Gemini seeing it as a bullish factor and Claude arguing it's lower than current valuation.
Potential acquisition by Big Pharma firms facing their own patent cliffs
Failure of zanzalintinib to show superiority over existing treatments in late-stage trials